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Abstract
Background: Intradialytic hypertension (IDH) increases morbidity and mortality. The prevalence in South Africa is unknown.
The pathogenesis is unclear, but it has been suggested that IDH may be due to subclinical ﬂuid overload. The objective of this
study was to determine the prevalence of IDH and to evaluate its association with ﬂuid overload using bioimpedance
spectroscopy (BIS).
Methods: A cross-sectional study involving 190 chronic haemodialysis patients in the Western Cape province of South Africa
was conducted between January 2013 and May 2014. IDH was deﬁned as a >10 mmHg increase in systolic blood pressure in at
least four of six prior consecutive haemodialysis sessions.
Results: The prevalence of IDHwas 28.4% (n = 54). Therewas a trend towards pre-dialysis overhydration in the IDH groupwhen
compared with controls {2.6 L [95% conﬁdence interval (CI) 1.7–3.4] versus 1.8 L [95% CI 1.4–2.1], respectively; P = 0.06} as
measured by BIS, but no difference in mean ultraﬁltration (UF) volume (2.4 versus 2.6 L; P = 0.30). A trend towards greater use of
antihypertensive drugs was noted in the IDH group [2.5 drugs (95% CI 2.15–2.87) versus 2.1 (95% CI 1.82–2.30); P = 0.05]. More
participants in the IDH group received calcium channel blockers (54 versus 36; P = 0.03).
Conclusions: The prevalence of IDH in our treatment centres is much higher than previously reported. Subclinical ﬂuid
overload may be a major contributing factor to the mechanism of this condition. The use of BIS identiﬁes patients who may
beneﬁt from additional UF.
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Background
A paradoxical increase in blood pressure (BP) during chronic
haemodialysis sessions, also known as intradialytic hyperten-
sion (IDH), is awell-known but uncommon complication. Various
deﬁnitions of IDH exist, but, to date, there is no standard deﬁn-
ition. As a result, the prevalence ranges from 5 to 15%, depending
on the deﬁnition used [1, 2]. A common deﬁnition is that by Inrig
et al. [3], who deﬁne IDHas a systolic blood pressure (SBP) increase
≥10 mmHg from pre- to post-hemodialysis in at least four of six
treatments.
IDH increases the incidence of cardiovascular morbidity and
mortality. A secondary analysis of 443 patients in the Crit-Line
Intradialytic Monitoring Beneﬁt Study (CLIMB) reported that
patients with an intradialytic increase in SBP had twice the risk
for hospitalization or death at 6months [3]. Analysis of 1748 inci-
dent haemodialysis patients in the United States Renal Data Sys-
tem (USRDS) found that the adjusted hazard for death at 2 years
for haemodialysis patientswas 6% for every 10 mmHg increase in
SBP [4].
The pathogenesis of IDH is likely to be multifactorial. Several
studies have identiﬁed extracellular ﬂuid overload as a primary
driver of this process [5–7]. Fluid overload increases stroke
volume, cardiac output and, subsequently, BP. In these studies,
patients with IDH not responsive to antihypertensivemedication
became normotensive after intensiﬁed ultraﬁltration (UF) [6–8].
Correction of ﬂuid status is labour intensive and often requires
extended dialysis sessions or aggressive UF. It may take weeks
to optimize the ﬂuid status of these patients, and BP may only
respond after a month of aggressive lowering in dry weight.
Other mechanisms thought to be involved in the pathogen-
esis include increased activity of the renin–angiotensin–aldoster-
one system (RAAS) and overactivity of the sympathetic nervous
system. Dialysate-related factors such as high dialysate sodium
and calcium concentrations as well as removal of dialysable
antihypertensive drugs may contribute [2, 9]. Erythropoietin-
stimulating agents (ESAs) have also been associated with the
development of hypertension in haemodialysis patients. ESAs
administered intravenously at the latter stage of a dialysis ses-
sion have been shown to increase mean arterial pressure (MAP)
by >10 mmHg during the interdialytic period [10]. Endothelial
dysfunction has also been implicated. The dialysis-related in-
crease in endothelin-1 (ET-1) concentrations and decrease in ni-
tric oxide (NO) have been documented in several studies [11, 12].
Owing to the paucity of randomized trials on the manage-
ment of IDH, treatment options have been largely driven by
expert opinion. Management is directed at all of the aforemen-
tioned pathogenic mechanisms, but normalizing ﬂuid overload
and dietary sodium is recommended as the ﬁrst step in manage-
ment [2]. Deﬁning the ﬂuid status of chronic haemodialysis
patients is difﬁcult. Most dialysis units adopt the traditional
‘trial and error’ method for determining dry weight. This is con-
sidered the point during dialysis at which the reduction in BP is
regarded by the clinician as too low after a speciﬁc volume has
been removed. However, this method relies heavily on clinical
judgement and is fraught with danger. Excessive ﬂuid removal
may result in intradialytic hypotension, whereas underestima-
tion of dry weight may cause ﬂuid overload with hypertension
and a subsequent increase in cardiovascular morbidity and
mortality.
Recently published randomized controlled trials advocate the
use of bioimpedance spectroscopy (BIS) to accurately determine
ﬂuid status in chronic haemodialysis patients [13, 14]. The vol-
ume of separate body ﬂuid compartments can be determined
using a body composition monitor (BCM). This device has
been validated against various gold standard methods [15].
Patients with ‘subclinical ﬂuid overload’ may be identiﬁed
using a BCM—a group often missed when traditional clinical
methods are used to determine dryweight. In particular, patients
with post-dialysis overhydration (OH) of the extracellular space
[extracellular water (ECW)] have been identiﬁed as being hyper-
tensive. Gradual dry weight adjustment using a BCM has been
shown to promote regression of left ventricular mass, reduced
arterial stiffness and reduced BP in these patients [14, 16].
Intradialytic hypotension is frequently encountered in chron-
ic haemodialysis patients. Nephrologists often focus their atten-
tion on prevention and management of this complication,
neglecting optimal management of patients with IDH. Early
identiﬁcation and management of IDH may reduce the burden
of cardiovascular complications.
To the best of our knowledge, there is no data on the preva-
lence of IDH in South Africa. Therefore, we conducted a cross-
sectional study to determine the prevalence of IDH in dialysis
units in the Western Cape province of South Africa. The second-
ary objectivewas to investigate any association between IDH and
interdialytic weight gain (IDWG), degree of ﬂuid overload as
assessed clinically and by BIS, quantity and timing of antihyper-
tensives, ESA dose and route of administration, time-averaged
sodium concentration, dialysate calcium concentration and
haemodialysis modality.
Methods
This study was registered at ClinicalTrials.gov (NCT01916668) on
1 February 2013. The studywas conducted in accordancewith the
ethical principles set out by the Declaration of Helsinki and
approval for the study was granted by the Human Research
Ethics Committee of Stellenbosch University (study number:
S12/10/264).
Study design, setting and participants
This multicentre, cross-sectional study of IDH in chronic haemo-
dialysis patients was conducted between January 2013 and May
2014 in the Western Cape province of South Africa.
Four haemodialysis units in theWestern Capewere used. One
unit was Tygerberg Academic Hospital in the public sector, with
the remaining units being Panorama, Athlone and Winelands
Kidney and Dialysis Centres in the private sector. All chronic
haemodialysis patients ≥18 years of age with the ability to give
informed consent were eligible. Patients who were unable to give
informed consent and had contraindications to BIS measurement
(limb amputations, pre-existing implanted cardiac devices such as
pacemakers or implantable cardioverter deﬁbrillators) received
>200 mL of intravenous ﬂuid or antibiotics for acute illness during
the dialysis session; those for whom BP could not bemeasured by
routine methods in the upper limbs were excluded (Figure 1). All
patients were studied during their midweek dialysis session.
Participants in the public sector were younger than those in
the private sector (Table 1). This is due to criteria used by the
Western Cape public sector when selecting patients for renal
replacement therapy (RRT). The age difference is also a reﬂection
of national differences in the age of those accessing public and
private sector treatment facilities [17]. Nearly half of the partici-
pants were of mixed race. This reﬂects the racial composition of
the population of theWestern Cape [18]. Data regarding the cause
of end-stage renal disease (ESRD) were not collected.
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Dialysis procedure
We deﬁned IDH as a ≥10 mmHg rise in SBP between pre- and
post-dialysis in at least four of six previous consecutive dialysis
sessions. BP, MAP and pulse rate were measured using standar-
dized online electronic BPmonitors before dialysis, hourly during
dialysis and up to 30 min after dialysis. Dialysate calcium levels
and time-averaged sodium concentrations were measured dur-
ing the procedure.
Bioimpedance monitoring
Patient weight was determined using an electronic standardized
weight scale. IDWG was calculated according to the following
formula: IDWG (kg) = pre-dialysis weight (kg) – post-dialysis
weight (kg) of the previous session. This IDWGwas used to deter-
mine the target total UF volume for the dialysis session.
Fluid status was estimated using BIS. Four electrodes were
attached to the ipsilateral arm and leg: two to the anterior aspect
of the arm [one at thewrist and one on the hand (4 cmapart)] and
two to the anterior aspect of the leg [one at the ankle and one on
the foot (4 cmapart)]. All participants had twoBISmeasurements
using a BCM before dialysis and ∼30 min after dialysis on a mid-
week dialysis day. ECW, intracellular water (ICW), total body
water (TBW), lean tissue mass/weight and volume of the fat com-
partment were subsequently determined.
Subclinical ﬂuid overload was deﬁned as normovolaemia as
judged by clinical assessment, but with positive OH as measured
by BIS.
Medication charts
Medication charts were reviewed for data regarding ESA dose, as
well as antihypertensive drug use and timing to the dialysis
procedure.
Statistical analysis
The primary aim of the study was to determine the prevalence of
IDH. A total of 190 participants were enrolled and were included
in the ﬁnal statistical analysis. Datawere analysed using Statisti-
ca 12 (2014) and SAS 9.1.3 (SAS Institute, Cary, NC, USA). Continu-
ous data were analysed using mean and standard deviation
(where normally distributed) and median and interquartile
range (where not normally distributed). Dichotomous data were
presented as frequencies and proportions and nominal data
were analysed with frequency distributions. To estimate
Fig. 1. Number of participants screened and included in the ﬁnal analysis.
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population parameters, 95% conﬁdence intervals (CIs) for means
and proportions were calculated.
For all continuous data other than BP, comparisons between
the IDH and control patients were performed using t-tests if data
were normally distributed, whereas non-normal distributed data
were analysed using the Mann–Whitney U test. Comparisons of
nominal data were performed using χ2 tests of independence.
Box plots were presented for these analyses, where appropriate.
BP data were measured at set time points during a dialysis
session. An analysis of variance (ANOVA) was performed to com-
pare group changes over time. Adjusted and unadjusted analyses
were also performed, where results were adjusted for the UF rate.
Mean and plot CIs were presented for these analyses. A signiﬁ-
cant P-value was regarded as ≤0.05.
Results
Baseline characteristics
Two hundred and twenty-three patients were screened. Two
hundred patientsmet inclusion criteria andwere recruited. How-
ever, three patients died before data collection, four patients
received intravenous ﬂuids on dialysis, two patients had faulty
BCM readings and the dialysis circuit of one of the patients
clotted.
One hundred and ninety patients were included in the ﬁnal
analysis. Fifty-four patients met the study deﬁnition of IDH.
The remaining patients (n = 136) were assigned to the control
group (Figure 1). The mean age of IDH patients was 57.1 years
(95% CI 52.8–61.2) and was similar to the control group (P = 0.42).
The proportion of males in the control group was greater than in
the IDH group; however, this difference was not statistically sig-
niﬁcant (P = 0.42). Similarly, there were no signiﬁcant racial dif-
ferences between groups (Table 1).
Primary outcome
Fifty-four of the 190 patients were found to have IDH, resulting in
a prevalence of 28.4% (95% CI 26–31.4).
Secondary outcomes
Pre-dialysis. The groups were well matched at baseline regarding
pre-dialysis weight, BMI, mode of dialysis, time on dialysis,
Table 1. Comparison of clinical baseline characteristics
All patients (n = 190) IDH (n = 54) Control (n = 136) P-value
Overall mean age (years) 55.7 (53.6–57.7) 57.1 (52.8–61.2) 55.1 (52.8–57.5) 0.42
Mean age by unit (years)
TBH (public) 43.9 (40.9–46.9) 38.0 (32.1–43.9) 46.0 (42.9–49.0) 0.02
AKDC 56.2 (51.7–60.8) 62.1 (54.6–69.7) 54.8 (49.7–59.9) 0.20
WKDC 57.3 (53.1–61.6) 58.2 (49.6–66.8) 56.9 (52.1–61.8) 0.78
PKDC 60.9 (57.6–64.2) 63.0 (57.8–68.2) 59.9 (55.7–64.1) 0.39
Males, n (%) 110.0 (58) 29.0 (53.7) 81.0 (59.5) 0.40
Race, n (%)
Black 26.0 (14.0) 6.0 (11.1) 20.0 (14.7) 0.23
Mixed 94.0 (49.5) 23.0 (42.6) 71.0 (52.2) 0.23
White 70.0 (37.0) 25.0 (46.3) 45.0 (33.1) 0.23
BP meds, n (%)
ACEI 63.0 (33.0) 22.0 (35.0) 41.0 (65.0) 0.16
ARB 29.0 (15.0) 8.0 (27.0) 21.0 (73.0) 0.91
α-blocker 33.0 (17.0) 13.0 (39.0) 20.0 (61.0) 0.12
β-blocker 91.0 (48.0) 29.0 (32.0) 62.0 (68.0) 0.31
CCB 104.0 (55.0) 36.0 (67.0) 68.0 (50.0) 0.03
Diuretic 91.0 (48.0) 25.0 (27.0) 66.0 (73.0) 0.78
Hydralazine 5.0 (0.03) 2.0 (40.0) 3.0 (60.0) 0.56
Minoxidil 2.0 (0.01) 1.0 (50.0) 1.0 (50.0) 0.50
BP meds 2.2 (1.9–2.4) 2.5 (2.2–2.9) 2.1 (1.8–2.3) 0.05
ESA dose (IU) 6532 (5890–7175) 6896 (5679–8293) 6352 (5611–7094) 0.62
Dialysis mode, n (%)
HD 39.0 (20) 10.0 (18) 29.0 (21) 0.67
HDF 151.0 (80) 44.0 (82) 107.0 (79) 0.67
Dialysis time (min/wk) 660.0 (648–672) 648.0 (618–678) 667.0 (648–678) 0.30
Pre-dialysis weight (kg) 77.0 (74.2–79.7) 74.5 (69.4–79.7) 77.9 (74.7–81.3) 0.29
BMI (kg/m2) 26.8 (25.9–27.6) 26.4 (24.7–28.0) 27.0 (26.0–28.0) 0.55
Pre-dialysis BP (mmHg)
Systolic 153.1 (149.5–157.1) 159.0 (152.7–165.5) 150.8 (146.3–155.3) 0.05
MAP 100.5 (98.2–103.0) 103.5 (99.6–107.3) 99.3 (96.4–102.2) 0.11
Pre-dialysis OH (L) 2.0 (1.7–2.4) 2.6 (1.7–3.5) 1.8 (1.4–2.2) 0.06
Pre-dialysis ECW (%) 10.4 (8.7–12.1) 10.4 (8.7–12.1) 9.6 (7.8–11.5) 0.12
Values expressed in a range in parentheses refer to 95% CIs; single values refer to percentage of total population.
IDH, intradialytic hypertension; TBH, Tygerberg Hospital; AKDC, Athlone Kidney and Dialysis Centre; WKDC, Winelands Kidney and Dialysis Centre; PKDC, Panorama
Kidney and Dialysis Centre; BP, blood pressure; meds, medication; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium
channel blocker; ESA, erythropoietin-stimulating agent; IU, international units; HD, haemodialysis; HDF, haemodiaﬁltration; BMI, body mass index; MAP, mean
arterial pressure; OH, overhydration; ECW, extracellular water.
Intradialytic hypertension during chronic haemodialysis | 639
C
L
IN
IC
A
L
K
ID
N
E
Y
JO
U
R
N
A
L
pre-dialysis BP, ESA dose and route of administration (Table 1).
The proportion of patients on calcium channel blockers (CCBs)
was greater in the IDH group. Thirty-six of 54 (67%) IDH patients
were using CCBs, compared with 68 of 136 (50%) control patients
(P = 0.03). There was a trend towards greater antihypertensive
drug use in the IDH group (2.5 versus 2.1; P = 0.05). There was no
signiﬁcant intergroup difference with regard to the use of other
antihypertensive medication or the timing of drug administra-
tion (pre- versus post-dialysis). A trend towards pre-dialysis OH
in the IDH group [2.6 L (95% CI 1.7–3.4) versus the control group
1.8 L (95% CI 1.4–2.1); P = 0.06] was noted (Figure 2).
Intra-dialysis. A statistically signiﬁcant difference in BP (systolic,
diastolic and MAP) was evident at all time points during the dia-
lysis session (P < 0.001) (Figure 3). The mean UF rate was margin-
ally higher in the control group (707.0 versus 609.4 mL/h);
however, this differencewas not statistically signiﬁcant (P = 0.52).
Time-averaged sodium concentration and dialysate calcium con-
centration were similar between groups (Table 2). The IDH group
had a mean weekly dialysis time of 648 min compared with the
control group’s 667 min (P = 0.26).
Post-dialysis. There was a trend towards post-dialysis OH in the
IDH group (+0.79 versus −0.17 L; P = 0.06). However, the propor-
tion of ECWpost-dialysis was greater in the IDH group (3.5 versus
1.4%; P = 0.04). There was no signiﬁcant difference between
groups regarding total UF volume [2.2 L (95% CI 1.9–2.5) versus
2.5 L (95% CI 2.3–2.7); P = 0.30] in the IDH versus control group, re-
spectively. Post-dialysis weight was similar [72.9 kg (95% CI 67.7–
78.0) versus 76.0 kg (95% CI 72.7–79.2); P = 0.29] in the IDH versus
control group, respectively (Table 2).
Discussion
The IDH prevalence of 28.4% found in this study is high. Van
Buren et al. [19] reviewed 22 955 haemodialysis treatments and
found a prevalence of 21.3 per 100 treatments and also reported
a persistent prevalence of 8% over an 8-month period. This latter
ﬁnding refutes the view that IDH may be a transient phenom-
enon. Nongnuch et al. [16] did a prospective audit of 531 patients
and found a prevalence of 18%. Prevalence may differ owing to
variations in deﬁning IDH. The aforementioned studies deﬁned
IDH as a ≥10 mmHg increase in SBP during the haemodialysis
Fig. 2. Pre-dialysis OH (in litres) in the IDH versus control group. IDH, intradialytic
hypertension.
Fig. 3. Mean intradialytic BP trend (in mmHg) during the 4 h of haemodialysis in those with IDH versus the control group. Note: Vertical lines represent 95% CIs. IDH,
intradialytic hypertension.
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session [16, 19]. However, the deﬁnition for the purposes of this
study included that this increase must have occurred in at least
four of six prior dialysis sessions. Despite this stricter deﬁnition,
the prevalence remainedhigh. Another factor thatmayhave con-
tributed to the higher prevalence we observed was the inclusion
of participants who had recently commenced haemodialysis.
Other researchers excluded patients recently placed onhaemodi-
alysis who had not reached clinically determined target dry
weights [16, 19]. Prevalence also differed within the four units,
with the highest prevalence found in the units with participants
who were of older age. Older age has previously been associated
with IDH. The reason for this remains unknown, but it may be re-
lated to arterial stiffness. Mourad et al. [20] compared aortic pulse
wave velocity (PWV) in those with haemodialysis-responsive BP
(deﬁned as a MAP decrease of >5% during dialysis) to those
with haemodialysis-unresponsive BP (deﬁned as an inability to
decrease MAP >5% during dialysis). PWV was greater in those
who were unresponsive, suggesting that arterial stiffness may
play a role in IDH. Of interest was that the unresponsive group
was older (mean age 58 years) compared with the responsive
group (mean age 54 years).
South Africa offers RRT in two sectors—private and public.
According to the 2012 South African Renal Registry, the overall
RRT rate was 164 per million population (pmp) [17]. This is con-
siderably lower than ﬁrst-world countries and other countries
with similar gross national products. However, in recent years
the private sector has grown exponentially, with current treat-
ment rates of 620 pmp. In contrast, the public sector RRT rate
has remained virtually unchanged over the past two decades at
only 73 pmp, mainly due to cost constraints. The Western Cape
provincial government instituted selection criteria for patients
with ESRD who are dependent on the public sector for RRT. The
resultant differences in participant characteristics in the public
sector may have affected its prevalence, as participants were
younger (Table 1) and none had underlying diabetes mellitus at
enrolment (personal communication with South African Renal
Registry).
Despite our deﬁnition of IDH, the high mean SBP remained
relatively constant in the IDH group throughout the dialysis
procedure, which suggests resistance to UF (Figure 3). However,
this could further be explained by the retrospective division of
participants into groups based on the prior six consecutive dialy-
sis sessions and subsequent prospective collection of BIS
measurements and dialysis data. Therefore, it is possible that
some of the participants classiﬁed as having IDH may not have
had a signiﬁcant increase in SBP on the day of data collection,
as treatment for IDH may already have been instituted at the
time of data collection.
Post-dialysis BIS measurements for OH and percentage ECW
revealed that the IDH group remained in a positive ﬂuid balance
whereas the control group achieved a negative balance (Table 2).
Participants were allowed to consume ﬂuids during dialysis, and
thismay have affected post-dialysis BISmeasurements. Interest-
ingly, the difference in mean reduction in weight correlated with
the difference in mean reduction in OH as measured by BIS;
however, target dry weights, and therefore UF volumes, which
were determined clinically, failed to identify this subclinical
ﬂuid overload. Similar ﬁndings using BIS measurements have
been reported previously, where it was found that the ECW:
TBW ratio before and after haemodialysis was greater in those
with IDHwhen comparedwith thosewho developed intradialytic
hypotension [16]. Therefore, BIS may provide a more objective
measure of hydration status when comparedwith clinical exam-
ination, particularly when no overt signs of ﬂuid overload are
present.
Both the IDH group and control group did not receive their full
720 min per week of dialysis. The IDH group had a mean weekly
dialysis time of 648 min, compared with 667 min in the control
group. Despite the fact that these intergroup differences were
not statistically signiﬁcant, they may be clinically relevant. The
IDH group received 60 min less dialysis per month, which could
have contributed to the subclinical ﬂuid overload. The Kidney
Disease Outcomes Quality Initiative clinical practice guidelines
recommend short, frequent dialysis sessions on a weekly basis,
which is deﬁned as <3 h/session for 5–7 sessions/week [21]. In
three randomized controlled trials, more frequent dialysis was
associated with improved BP control when compared with con-
ventional haemodialysis [22–24].
A sodium gradient favouring the net absorption of sodium
during the haemodialysis session may contribute to the patho-
genesis of IDH [25]. A shortcoming of this study was determin-
ation of the time-averaged sodium concentration rather than
the sodium gradient. A low calcium dialysate bath has been
shown to mitigate post-dialysis hypertension [26]. However,
there was no association between IDH and dialysate calcium
concentration in this study.
Table 2. Comparison of intradialytic and post-dialysis clinical parameters
All patients (n = 190) IDH (n = 54) Control (n = 136) P-value
Overall prevalence, n (%) 54 (28.4) 136 (71.6)
Prevalence by unit, n (%)
TBH 39 (20.5) 10 (25.6) 29 (74.4)
AKDC 36 (19.0) 7 (19.4) 29 (81.0)
WKDC 45 (23.7) 14 (31.1) 31 (68.9)
PKDC 70 (36.8) 23 (32.9) 47 (67.1)
Dialysate Ca2+(mmol/L) 1.36 (1.33–1.39) 1.34 (1.29–1.39) 1.36 (1.33–1.40) 0.45
Time avg. Na+ (mmol/L) 138.4 (138.1–138.7) 138.3 (137.7–139) 138.4 (138.1–138.8) 0.72
UF rate (mL/h) 679.0 (573.5–784.5) 609.4 (525.3–693.5) 707.0 (562.6–851.5) 0.52
UF volume (L) 2.4 (2.2–2.5) 2.2 (1.9–2.5) 2.5 (2.3–2.7) 0.30
Post-dialysis OH (L) 0.082 (−0.26–0.42) 0.79 (−0.04–1.62) −0.17 (−0.52–0.18) 0.06
Post-dialysis ECW (%) −0.001 (−0.02–0.02) 3.50 (−1.40–8.50) −1.40 (−3.70–0.80) 0.04
Post-dialysis weight (kg) 75.1 (72.4–77.8) 72.9 (67.7–78.1) 76.0 (72.8–79.2) 0.31
Values expressed in a range in parentheses refer to 95% CIs; single values refer to percentage of total population.
TBH, Tygerberg Hospital; AKDC, Athlone Kidney and Dialysis Centre; WKDC, Winelands Kidney and Dialysis Centre; PKDC, Panorama Kidney and Dialysis Centre; avg.,
averaged; UF, ultraﬁltration; OH, overhydration; ECW, extracellular water.
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Recently, several studies have implicated endothelial dys-
function as the main factor in the pathogenesis of IDH. It
has been reported that serum ET-1 concentrations increase in
thosewith a rise in BP during haemodialysis, while changes in ni-
trate/nitrite concentrations are comparable in those without an
increase in BP [27].
The IDH group were using marginally more antihyperten-
sives, and in particular more CCBs. CCBs cause pre-capillary
vasodilatation resulting in high capillary hydrostatic pressure
and subsequent oedema [28]. This may partly explain the trend
towards pre-dialysis OH in the IDH group. BPmedication thought
to mitigate the intradialytic rise in BP is mainly angiotensin-
converting enzyme inhibitors (ACEIs), angiotensin II receptor
blockers (ARBs) and beta blockers. ACEI and ARBs reduce RAAS
activity, whereas β-blockers (especially carvedilol) have shown
to reduce endothelial dysfunction [11]. It is interesting that in
this study, the proportion of IDH patients on these agents was
lower than in the control group. However, this difference was
not signiﬁcant. Chou et al. [12] reported that RAAS and sympa-
thetic overactivity were unlikely to play a role in the genesis of
IDH. It has been suggested that removal of water-soluble antihy-
pertensives during haemodialysis may contribute to IDH; how-
ever, this could not be veriﬁed.
ESAs administered in high doses are believed to cause hyper-
tension by increasing vascular stiffness as well as increasing
blood viscosity, leading to endothelial damage [2]. There was no
signiﬁcant difference between groups with regard to ESA dose.
ESAs were administered intravenously in the private units and
subcutaneously in the public unit. We could not establish any as-
sociation between the route of ESA administration and IDH.
Management of this condition is focussed on ﬂuid removal
over a sustained period of time, as demonstrated in the dry-
weight reduction in hypertensive hemodialysis patients trial
[29]. This is achieved by dialysing patients longer and/or more
frequently, which increases dialysis costs. In addition, treatment
of hypertension and endothelial dysfunction necessitates the
use of non-dialysable, antihypertensive drugs such as ARBs
and carvedilol. These management strategies may not be prac-
tical in busy units already functioning at full capacity.
BIS is used sparingly in the private sector and not at all in the
public sector. The cost of consumables is the major reason for
this. Clinical assessment is notorious for providing a poor esti-
mate of hydration status, but the routine use of BIS for determin-
ing pre-dialysis hydration status and setting more accurate UF
targets may assist in mitigating IDH and its deleterious
consequences.
Limitations
The prevalence may have differed had we used an alternative
deﬁnition. The inclusion of younger participants from the public
sector may have affected the overall prevalence, as IDH has pre-
viously been reported to occur more frequently in older patients.
As this was a cross-sectional study, a cause-and-effect relation-
ship between IDH and subclinical ﬂuid overload cannot be
made. The primary aim of this studywas the estimation of preva-
lence. A larger cohort may be required to ﬁnd a statistical signiﬁ-
cance regarding the association between subclinical ﬂuid
overload and IDH.
Conclusion
This study has indicated that the prevalence of IDH is higher than
that reported in the literature. Subclinical ﬂuid overloadmay be a
major contributing factor to the mechanism of this condition. As
clinical assessment of hydration status is poor, BIS may be used
to assist in identifying IDH patients with subclinical ﬂuid over-
load who may beneﬁt from additional UF.
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